• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
AYLA

AYLA

Ayala Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyIL

USD0.53

+0.00 (+0.00%)

Company Profile

CEO

Roni Mamluk

IPO Date

2020-05-08

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

IL

Market Metrics

Open

$0.49

Prev. Close

$0.53

Day Low

$0.44

Day High

$0.57

52W Low

$0.36

52W High

$5.94

Volume

0.14M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

32.8%

Avg Negative

11.9%

Avg Neutral

55.6%

News Feed

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research·8/13/2021·↑ positive

Recap: Ayala Pharmaceuticals Q2 Earnings

Benzinga·8/13/2021·↓ negative

Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewsWire·8/13/2021·↑ positive

Will Ayala Pharmaceuticals, Inc. (AYLA) Report Negative Q2 Earnings? What You Should Know

Zacks Investment Research·8/5/2021·↑ positive

AYLA Stock Increased 3.3%: Why It Happened

Pulse2·7/13/2021·↑ positive

Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

GlobeNewsWire·7/6/2021·↑ positive

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/14/2021·↑ positive

Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewsWire·5/14/2021·↑ positive

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma

GlobeNewsWire·4/21/2021·↑ positive

Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors

Benzinga·2/19/2021·↑ positive